David E I Pyott sold $1.1M of ALNY
director at ALNYLAM PHARMACEUTICALS, INC.. 3,830 shares at an average of $299.18, traded Jun 1, 2026, filed Jun 3, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 71% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178670-26-000048, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | MOption exercise Common Stock10b5-1 | +3,830 | $0.00 | $0 | 5,412 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -921 | $297.71 | $274k | 4,491 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,175 | $298.91 | $351k | 3,316 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,222 | $299.87 | $366k | 2,094 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -495 | $300.72 | $149k | 1,599 | Jun 3, 2026 |
| Jun 1, 2026 | SOpen-market sale Common Stock10b5-1 | -17 | $302.65 | $5,145 | 1,582 | Jun 3, 2026 |
| Jun 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,830 | $0.00 | $0 | 0 | Jun 3, 2026 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.